CHEMILUMINESCENCE IMMUNOASSAY MARKET ANALYSIS

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

Technological advancements in CLIA diagnostic platforms

Technological advancements are drastically transforming the chemiluminescence immunoassay (CLIA) diagnostic platforms. . Several innovative CLIA analyzers have widened the scope of CLIA testing. The new generation fully automated, high throughput CLIA analyzers offer enhanced sensitivity, specificity, faster turn-around-time and expanded assay menus as compared to conventional immunoassay technologies. For instance, as per World Health Organization in 2022, the Liaison range of CLIA analyzers by DiaSorin can perform a wide variety of routine and specialty tests including therapeutic drug monitoring, endocrinology, oncology, infectious diseases from a small patient sample volume in a single analytical run. (Furthermore, software and digital innovations are revolutionizing the CLIA diagnostic platforms. Many new systems are integrated with artificial intelligence (AI) and machine learning capabilities. This allows automated interpretation of test results, flagging of outliers, improved quality control, customized report generations and remote diagnostics. Cloud connectivity in some systems ensures real-time data access for clinicians from different locations. For instance, the Affinity total laboratory automation solution from Siemens Healthineers uses AI to automate repetitive tasks, standardized workflows and predictive maintenance to maximize efficiency. . According to the data published by the United Nations, non-communicable diseases and healthcare needs of an ageing global population will rise substantially in the future. COVID-19 pandemic witnessed exponential increase in infectious disease testing worldwide using CLIA platforms. This further underscores the necessity of rapid, automated and high-throughput CLIA technology for quality diagnostic services.